- Expanded characterization of CD3-binding antibodies includes
identification of antibodies that bind regions of CD3 that are
distinct from commonly used molecules
- Robust proof-of-concept study demonstrates T-cell engagers that
potently eliminate cancer cells with minimal cytokine release
AbCellera (Nasdaq: ABCL) today announced the release of new data
on its T-cell engager (TCE) platform at the Society for
Immunotherapy of Cancer (SITC) 37th Annual Meeting, to be held
virtually and at the Boston Convention & Exhibition Center from
November 8 to 12, 2022. AbCellera’s poster presentation describes
the expansion, further characterization, and validation of a
diverse panel of CD3-binding antibodies that can be used to develop
T-cell engagers for cancer treatments.
“The robust data package we are presenting at SITC demonstrates
that our panel includes antibodies that are distinct from molecules
commonly used for CD3 T-cell engager development,” said Bo
Barnhart, Ph.D., VP, Translational Research at AbCellera. “By
combining this panel with the OrthoMab bispecifics platform and
high-throughput antibody analytics, we have shown that we can
rapidly identify developable T-cell engagers that balance potent
cytotoxicity and low cytokine release.”
CD3 T-cell engagers are bispecific antibodies that redirect T
cells to kill tumor cells. Developing effective T-cell engagers
requires two parental antibodies: a CD3-binding arm that fine-tunes
T-cell activation and a tumor-binding arm with high specificity for
cancer cells. Pairs of parental antibodies that work well together
are rare, creating a need for diverse panels of developable
antibodies that can be combined and tested at scale to find optimal
clinical candidates.
To address the paucity of anti-CD3 antibodies for TCEs,
AbCellera used its integrated antibody discovery, characterization,
and engineering technologies to discover and validate an extensive
panel of fully human CD3-binding antibodies. New data presented at
SITC includes epitope binning analysis, revealing antibodies with
species cross-reactivity that bind epitopes distinct from commonly
used parental antibodies, such as SP34-2. AbCellera also conducted
a second discovery campaign strategically designed to enhance the
number of cross-reactive antibodies in the panel, resulting in
hundreds of additional unique antibody sequences to be
characterized.
Developing bispecific antibodies that potently eliminate cancer
cells without inducing toxicity has been a significant challenge
limiting T-cell engager development. In a proof-of-concept study,
AbCellera used its OrthoMabTM bispecifics platform to create CD3 x
EGFR T-cell engagers. High-throughput functional and biophysical
assays identified potent tumor-cell killing T-cell engager
molecules that maintained low levels of cytokine production without
the need for further engineering or optimization.
“We debuted our T-cell engager platform at the AACR annual
meeting in April of this year, and in less than six months, we have
greatly expanded the data package supporting this platform,” said
Murray McCutcheon, Ph.D., Senior VP, Corporate Development at
AbCellera. “The remarkable progress demonstrates the speed of
AbCellera’s antibody discovery engine, the quality of the
antibodies in our T-cell engager panel, and the potential impact it
has for partners looking to accelerate development of new cancer
treatments.”
Details on AbCellera’s presentation at SITC are as
follows:
Title: Streamlining T-cell engager development with a
diverse panel of fully human CD3-binding antibodies, bispecific
engineering technology, and an integrated discovery engine
Poster Number: 1196 Date and Time: Friday, November
11, 9:00 a.m. to 8:30 p.m. ET Location: Boston Convention
& Exhibition Center, Hall C or online at
https://www.sitcancer.org/2022/home
The poster is available for viewing here.
About AbCellera Biologics Inc. AbCellera is a technology
company that searches, decodes, and analyzes natural immune systems
to find antibodies that its partners can develop into drugs to
prevent and treat disease. AbCellera partners with drug developers
of all sizes, from large pharmaceutical to small biotechnology
companies, empowering them to move quickly, reduce cost, and tackle
the toughest problems in drug development. For more information,
please visit www.abcellera.com
AbCellera Forward-looking Statements This press release
contains forward-looking statements, including statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements are
based on management’s current beliefs and assumptions and on
information currently available to management. All statements
contained in this release other than statements of historical fact
are forward-looking statements, including statements regarding our
ability to develop, commercialize and achieve market acceptance of
our current and planned products and services, our research and
development efforts, and other matters regarding our business
strategies, use of capital, results of operations and financial
position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
Source: AbCellera Biologics Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221109005958/en/
Inquiries Media: Jessica Yingling, Ph.D.;
media@abcellera.com, +1(236)521-6774 Business Development: Murray
McCutcheon, Ph.D.; bd@abcellera.com, +1(604)559-9005 Investor
Relations: Josephine Hellschlienger, Ph.D.; ir@abcellera.com,
+1(778)729-9116
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Lug 2023 a Lug 2024